UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries

UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint. Neither the low dose nor high dose resulted in patients seeing a benefit, the company ...